Kamada Ltd. announced it was awarded a three-year contract with an international organization for the supply of its proprietary products, KAMRAB® and VARIZIG®, in Latin America. The contract spans from 2025 to 2027, with total expected revenue estimated at approximately $25 million.
The portion of revenue expected for the calendar year 2025 from this contract has already been incorporated into the company’s recently announced 2025 revenue guidance. This agreement highlights the global strength of Kamada's leading specialty immunoglobulin portfolio.
KAMRAB® is indicated for post-exposure prevention of rabies infection, while VARIZIG® is a Varicella Zoster Immune Globulin (Human) for post-exposure prophylaxis in high-risk individuals. This contract is indicative of the substantial commercial potential for Kamada's broad product portfolio in international markets.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.